Literature DB >> 34174530

Practical management and assessment of primary plasma cell leukemia in the novel agent era.

A Visram1, A Suska2, A Jurczyszyn2, W I Gonsalves3.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34174530      PMCID： PMC8405542          DOI： 10.1016/j.ctarc.2021.100414

Source DB:  PubMed          Journal:  Cancer Treat Res Commun        ISSN： 2468-2942


× No keyword cloud information.
  79 in total

1.  Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.

Authors:  Eirini Katodritou; Evangelos Terpos; Charikleia Kelaidi; Maria Kotsopoulou; Sossana Delimpasi; Marie-Christine Kyrtsonis; Argiris Symeonidis; Nikos Giannakoulas; Aikaterini Stefanoudaki; Dimitrios Christoulas; Christina Chatziaggelidou; Vassiliki Gastari; Nikos Spyridis; Evgenia Verrou; Pavlina Konstantinidou; Kostas Zervas; Meletios A Dimopoulos
Journal:  Am J Hematol       Date:  2013-11-21       Impact factor: 10.047

2.  Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation.

Authors:  Melissa Alsina; Pamela S Becker; Xiaobo Zhong; Alexia Adams; Parameswaran Hari; Scott Rowley; Edward A Stadtmauer; David H Vesole; Brent Logan; Daniel Weisdorf; Muzaffar Qazilbash; Leslie L Popplewell; Brian McClune; William Bensinger; Marcie Riches; Sergio A Giralt; Marcelo C Pasquini
Journal:  Biol Blood Marrow Transplant       Date:  2014-04-21       Impact factor: 5.742

3.  Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).

Authors:  Tomas Jelinek; Jana Mihalyova; Michal Kascak; Juraj Duras; Tereza Popkova; Katerina Benkova; Petra Richterova; Hana Plonkova; Jana Zuchnicka; Lucie Broskevicova; Lucie Huvarova; Lucie Cerna; Katerina Growkova; Michal Simicek; Martin Havel; Jaromir Gumulec; Milan Navratil; Zdenek Koristek; Bruno Paiva; Roman Hajek
Journal:  Am J Hematol       Date:  2018-11-25       Impact factor: 10.047

4.  Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States.

Authors:  Luciano J Costa; Ilene K Brill; James Omel; Kelly Godby; Shaji K Kumar; Elizabeth E Brown
Journal:  Blood Adv       Date:  2017-01-04

5.  MYC amplification on double minute chromosomes in plasma cell leukemia with double IGH/CCND1 fusion genes.

Authors:  Katsuya Yamamoto; Kimikazu Yakushijin; Mitsuhiro Ito; Hideaki Goto; Ako Higashime; Kazuyoshi Kajimoto; Yoshitake Hayashi; Hiroshi Matsuoka; Hironobu Minami
Journal:  Cancer Genet       Date:  2020-01-27

6.  Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.

Authors:  Ajai Chari; Kejal Parikh; Quanhong Ni; Safiya Abouzaid
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-06-18

7.  B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.

Authors:  Robert O Carpenter; Moses O Evbuomwan; Stefania Pittaluga; Jeremy J Rose; Mark Raffeld; Shicheng Yang; Ronald E Gress; Frances T Hakim; James N Kochenderfer
Journal:  Clin Cancer Res       Date:  2013-01-23       Impact factor: 12.531

8.  Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14).

Authors:  Wilson I Gonsalves; Francis K Buadi; Shaji K Kumar
Journal:  Eur J Haematol       Date:  2017-11-16       Impact factor: 2.997

Review 9.  International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Authors:  Shaji Kumar; Bruno Paiva; Kenneth C Anderson; Brian Durie; Ola Landgren; Philippe Moreau; Nikhil Munshi; Sagar Lonial; Joan Bladé; Maria-Victoria Mateos; Meletios Dimopoulos; Efstathios Kastritis; Mario Boccadoro; Robert Orlowski; Hartmut Goldschmidt; Andrew Spencer; Jian Hou; Wee Joo Chng; Saad Z Usmani; Elena Zamagni; Kazuyuki Shimizu; Sundar Jagannath; Hans E Johnsen; Evangelos Terpos; Anthony Reiman; Robert A Kyle; Pieter Sonneveld; Paul G Richardson; Philip McCarthy; Heinz Ludwig; Wenming Chen; Michele Cavo; Jean-Luc Harousseau; Suzanne Lentzsch; Jens Hillengass; Antonio Palumbo; Alberto Orfao; S Vincent Rajkumar; Jesus San Miguel; Herve Avet-Loiseau
Journal:  Lancet Oncol       Date:  2016-08       Impact factor: 41.316

10.  Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background.

Authors:  Elizabeta A Rojas; Luis A Corchete; María Victoria Mateos; Ramón García-Sanz; Irena Misiewicz-Krzeminska; Norma C Gutiérrez
Journal:  Blood Cancer J       Date:  2019-11-20       Impact factor: 11.037
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.